FibroBiologics (NASDAQ:FBLG) Earns Buy Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $16.00 target price on the stock.

Several other brokerages also recently commented on FBLG. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of FibroBiologics in a research report on Thursday, February 13th. Rodman & Renshaw began coverage on shares of FibroBiologics in a research report on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, FibroBiologics presently has an average rating of “Buy” and an average price target of $13.00.

FibroBiologics Stock Performance

FBLG stock traded up $0.05 during trading on Thursday, hitting $1.19. 103,993 shares of the stock traded hands, compared to its average volume of 369,335. FibroBiologics has a 1 year low of $0.98 and a 1 year high of $14.70. The firm’s 50 day moving average is $1.75 and its two-hundred day moving average is $2.28.

Hedge Funds Weigh In On FibroBiologics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Intech Investment Management LLC bought a new position in FibroBiologics during the 4th quarter valued at about $25,000. Virtu Financial LLC bought a new position in FibroBiologics during the 4th quarter valued at about $30,000. The Manufacturers Life Insurance Company bought a new position in FibroBiologics during the 3rd quarter valued at about $32,000. Jane Street Group LLC bought a new position in FibroBiologics during the 3rd quarter valued at about $37,000. Finally, Raymond James Financial Inc. bought a new position in FibroBiologics during the 4th quarter valued at about $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.